CIZZLE BIOTECHNOLOGY HOLDINGS PLC Financials Cizzle Biotechnology Holdings Plc
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.675 GBX | 0.00% |
|
-1.47% | -14.10% |
| Apr. 30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| Apr. 30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 7.603 | 5.034 | 7.095 |
| Enterprise Value (EV) 1 | 6.728 | 4.556 | 5.538 |
| P/E ratio | -1.23 x | -4.63 x | -4.04 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | 2,581,653 x | -6,760,956 x | -32,385,462 x |
| FCF Yield | 0% | -0% | -0% |
| Price to Book | 8.11 x | 1.87 x | 4.71 x |
| Nbr of stocks (in thousands) | 253,448 | 347,175 | 363,842 |
| Reference price 2 | 0.0300 | 0.0145 | 0.0195 |
| Announcement Date | 6/21/22 | 4/27/23 | 4/30/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.025 | - | - | - | - | - |
| EBITDA 1 | -0.0264 | -0.0203 | - | - | - | - |
| EBIT 1 | -0.0279 | -0.0217 | -0.014 | -0.798 | -0.963 | -0.976 |
| Operating Margin | -111.57% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.0279 | -0.0217 | -0.014 | -3.958 | -0.963 | -1.763 |
| Net income 1 | -0.0279 | -0.0217 | -0.014 | -3.921 | -0.912 | -1.717 |
| Net margin | -111.54% | - | - | - | - | - |
| EPS 2 | -0.0888 | -0.0691 | -0.0283 | -0.0244 | -0.003130 | -0.004824 |
| Free Cash Flow | - | 0.001067 | -0.009936 | 2.606 | -0.6739 | -0.171 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/21/19 | 4/23/21 | 6/21/22 | 6/21/22 | 4/27/23 | 4/30/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0 | - | - | - |
| Net Cash position 1 | 0.02 | 0.01 | - | 0.88 | 0.48 | 1.56 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 0 | -0.01 | 2.61 | -0.67 | -0.17 |
| ROE (net income / shareholders' equity) | -161% | -124% | 2,047% | -844% | -51% | -82.8% |
| ROA (Net income/ Total Assets) | -51.9% | -41.4% | -66.1% | -85.6% | -30.6% | -27.2% |
| Assets 1 | 0.0537 | 0.0524 | 0.0212 | 4.579 | 2.985 | 6.302 |
| Book Value Per Share 2 | 0.0100 | 0.0200 | -0.0200 | 0 | 0.0100 | 0 |
| Cash Flow per Share 2 | 0.0600 | 0.0400 | 0.0100 | 0 | 0 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/21/19 | 4/23/21 | 6/21/22 | 6/21/22 | 4/27/23 | 4/30/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 8.44M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- PSL Stock
- Financials Cizzle Biotechnology Holdings Plc
